Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow

🇺🇸 Seeking Alpha (US) —

AI Summary

A slideshow accompanies Rocket Pharmaceuticals' update on its Danon disease program and the pivotal RP-A501 trial. The supplied text does not include further clinical findings.

Markets Health Rocket Pharmaceuticals Danon disease RP-A501 clinical trial gene therapy clinical data

Read original source →